These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35182542)

  • 21. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.
    Kumar R; Hauser RA; Mostillo J; Dronamraju N; Graf A; Merschhemke M; Kenney C
    Int J Neurosci; 2016; 126(1):20-4. PubMed ID: 24007304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiparkinson prodrugs.
    Di Stefano A; Sozio P; Cerasa LS
    Molecules; 2008 Jan; 13(1):46-68. PubMed ID: 18259129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
    Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP
    J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors and safe dosage of levodopa for wearing-off phenomenon in Chinese patients with Parkinson's disease.
    Chen H; Fang J; Li F; Gao L; Feng T
    Neurol Sci; 2015 Jul; 36(7):1217-23. PubMed ID: 25616444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hallmarks of Treatment Aspects: Parkinson's Disease Throughout Centuries Including l-Dopa.
    Kim HJ; Jeon BS; Jenner P
    Int Rev Neurobiol; 2017; 132():295-343. PubMed ID: 28554412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deuterium-substituted L-DOPA displays increased behavioral potency and dopamine output in an animal model of Parkinson's disease: comparison with the effects produced by L-DOPA and an MAO-B inhibitor.
    Malmlöf T; Feltmann K; Konradsson-Geuken Å; Schneider F; Alken RG; Svensson TH; Schilström B
    J Neural Transm (Vienna); 2015 Feb; 122(2):259-72. PubMed ID: 24906468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies.
    Molloy SA; Rowan EN; O'Brien JT; McKeith IG; Wesnes K; Burn DJ
    J Neurol Neurosurg Psychiatry; 2006 Dec; 77(12):1323-8. PubMed ID: 16952917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
    Oertel W; Schulz JB
    J Neurochem; 2016 Oct; 139 Suppl 1():325-337. PubMed ID: 27577098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New insights into pathogenesis of l-DOPA-induced dyskinesia.
    Zheng C; Zhang F
    Neurotoxicology; 2021 Sep; 86():104-113. PubMed ID: 34331976
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson's disease.
    Devos D; Lejeune S; Cormier-Dequaire F; Tahiri K; Charbonnier-Beaupel F; Rouaix N; Duhamel A; Sablonnière B; Bonnet AM; Bonnet C; Zahr N; Costentin J; Vidailhet M; Corvol JC
    Parkinsonism Relat Disord; 2014 Feb; 20(2):170-5. PubMed ID: 24216088
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parkinson's disease: medical and surgical treatment.
    Ahlskog JE
    Neurol Clin; 2001 Aug; 19(3):579-605, vi. PubMed ID: 11532645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levodopa Effect and Motor Function in Late Stage Parkinson's Disease.
    Rosqvist K; Horne M; Hagell P; Iwarsson S; Nilsson MH; Odin P
    J Parkinsons Dis; 2018; 8(1):59-70. PubMed ID: 29480220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The medical treatment of Parkinson disease from James Parkinson to George Cotzias.
    Fahn S
    Mov Disord; 2015 Jan; 30(1):4-18. PubMed ID: 25491387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Self-assembled polydopamine nanoparticles improve treatment in Parkinson's disease model mice and suppress dopamine-induced dyskinesia.
    Vong LB; Sato Y; Chonpathompikunlert P; Tanasawet S; Hutamekalin P; Nagasaki Y
    Acta Biomater; 2020 Jun; 109():220-228. PubMed ID: 32268242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease.
    Metman LV; Gillespie M; Farmer C; Bibbiani F; Konitsiotis S; Morris M; Shill H; Bara-Jimenez W; Mouradian MM; Chase TN
    Clin Neuropharmacol; 2001; 24(3):163-9. PubMed ID: 11391128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?
    Del-Bel E; Bortolanza M; Dos-Santos-Pereira M; Bariotto K; Raisman-Vozari R
    Synapse; 2016 Dec; 70(12):479-500. PubMed ID: 27618286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Analysis of sustained attention in patients with Parkinson's disease being treated with dopamine precursors].
    Luque-Moreno C; López-García JC; Díaz-Argandoña E
    Rev Neurol; 2012 Sep; 55(5):257-62. PubMed ID: 22930136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy.
    Fischer PA
    J Neural Transm Suppl; 1995; 46():381-9. PubMed ID: 8821073
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and pharmacokinetic evaluation of L-dopa and cabergoline cotreatment in Parkinson's disease.
    Del Dotto P; Colzi A; Musatti E; Strolin Benedetti M; Persiani S; Fariello R; Bonuccelli U
    Clin Neuropharmacol; 1997 Oct; 20(5):455-65. PubMed ID: 9331523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.